Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BeiGene, Ltd. stock logo
BGNE
BeiGene
$194.32
$146.21
$248.16
$18.03B0.57336,748 shs331,608 shs
Catalent, Inc. stock logo
CTLT
Catalent
$63.48
$62.87
$57.52
$63.50
$11.52B1.152.05 million shsN/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$14.90
-1.0%
$13.45
$8.02
$15.78
$7.40B1.675.07 million shs3.84 million shs
Mylan stock logo
MYL
Mylan
$15.86
$15.57
$12.75
$23.11
$8.59B1.456.49 million shs4,016 shs
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$18.17
-4.7%
$30.98
$16.88
$154.13
$1.79B0.452.25 million shs3.08 million shs
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BeiGene, Ltd. stock logo
BGNE
BeiGene
0.00%0.00%0.00%0.00%+26.48%
Catalent, Inc. stock logo
CTLT
Catalent
0.00%0.00%0.00%0.00%+10.53%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.00%+1.75%+4.98%+72.41%+12.08%
Mylan stock logo
MYL
Mylan
0.00%0.00%0.00%0.00%0.00%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
0.00%-0.25%-51.30%-64.39%-87.83%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BeiGene, Ltd. stock logo
BGNE
BeiGene
N/AN/AN/AN/AN/AN/AN/AN/A
Catalent, Inc. stock logo
CTLT
Catalent
1.0564 of 5 stars
1.00.00.04.60.00.01.9
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
1.4963 of 5 stars
1.31.00.00.32.01.71.3
Mylan stock logo
MYL
Mylan
0.7181 of 5 stars
0.00.00.03.50.01.71.3
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
4.7171 of 5 stars
4.22.00.04.22.41.71.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BeiGene, Ltd. stock logo
BGNE
BeiGene
3.00
Buy$274.20∞ Upside
Catalent, Inc. stock logo
CTLT
Catalent
2.00
Hold$63.500.03% Upside
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
2.50
Moderate Buy$15.332.94% Upside
Mylan stock logo
MYL
Mylan
0.00
N/AN/AN/A
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
2.44
Hold$58.54222.19% Upside

Current Analyst Ratings Breakdown

Latest CTLT, SRPT, MYL, BGNE, and ELAN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/10/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$30.00 ➝ $28.00
7/2/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$16.00 ➝ $17.00
6/26/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform
6/25/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Sell
6/20/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$123.00 ➝ $45.00
6/20/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Market Perform
6/18/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$85.00 ➝ $40.00
6/18/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$24.00
6/17/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$50.00 ➝ $25.00
6/17/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold$29.00
6/17/2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$60.00 ➝ $30.00
(Data available from 7/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BeiGene, Ltd. stock logo
BGNE
BeiGene
$3.32B0.00N/AN/A$37.10 per share0.00
Catalent, Inc. stock logo
CTLT
Catalent
$4.38B2.63$2.64 per share24.04$19.91 per share3.19
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$4.43B1.67$2.25 per share6.61$12.33 per share1.21
Mylan stock logo
MYL
Mylan
$11.50B0.75$8.76 per share1.81$23.02 per share0.69
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$1.90B0.94$2.44 per share7.46$15.99 per share1.14
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BeiGene, Ltd. stock logo
BGNE
BeiGene
-$881.71M-$8.24N/AN/AN/A-25.94%-25.12%-14.95%N/A
Catalent, Inc. stock logo
CTLT
Catalent
-$1.04B-$2.26N/A47.022.69-9.28%-0.66%-0.24%N/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$338M$0.7420.1316.742.918.43%7.54%3.57%8/7/2025 (Estimated)
Mylan stock logo
MYL
Mylan
$16.80M$4.4229.923.522.012.35%20.43%7.72%N/A
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$235.24M-$2.69N/A1.66N/A-11.12%-14.88%-5.12%8/6/2025 (Estimated)

Latest CTLT, SRPT, MYL, BGNE, and ELAN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.1989N/AN/AN/A$1.19 billionN/A
8/6/2025Q2 2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$0.89N/AN/AN/A$530.66 millionN/A
5/7/2025Q1 2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.31$0.37+$0.06$0.14$1.17 billion$1.19 billion
5/6/2025Q1 2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$2.20-$3.42-$5.62-$4.60$685.75 million$744.86 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BeiGene, Ltd. stock logo
BGNE
BeiGene
N/AN/AN/AN/AN/A
Catalent, Inc. stock logo
CTLT
Catalent
N/AN/AN/AN/AN/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
N/AN/AN/AN/AN/A
Mylan stock logo
MYL
Mylan
N/AN/AN/AN/AN/A
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BeiGene, Ltd. stock logo
BGNE
BeiGene
0.05
1.93
1.72
Catalent, Inc. stock logo
CTLT
Catalent
1.38
2.51
1.96
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.68
2.71
1.46
Mylan stock logo
MYL
Mylan
0.84
0.93
0.53
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
1.00
4.02
2.46

Institutional Ownership

CompanyInstitutional Ownership
BeiGene, Ltd. stock logo
BGNE
BeiGene
48.55%
Catalent, Inc. stock logo
CTLT
Catalent
N/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
97.48%
Mylan stock logo
MYL
Mylan
88.18%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
86.68%

Insider Ownership

CompanyInsider Ownership
BeiGene, Ltd. stock logo
BGNE
BeiGene
7.43%
Catalent, Inc. stock logo
CTLT
Catalent
0.31%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.89%
Mylan stock logo
MYL
Mylan
0.59%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
7.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
BeiGene, Ltd. stock logo
BGNE
BeiGene
9,00097.62 million90.20 millionOptionable
Catalent, Inc. stock logo
CTLT
Catalent
16,900181.51 million180.95 millionOptionable
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
9,000496.65 million492.23 millionOptionable
Mylan stock logo
MYL
Mylan
35,000541.55 millionN/AOptionable
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
1,37298.28 million90.71 millionOptionable

Recent News About These Companies

Zacks Research Has Optimistic Outlook of SRPT Q2 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

BeiGene stock logo

BeiGene NASDAQ:BGNE

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC. The company is also developing inhibitors comprising Sonrotoclax (BGB-11417), BGB-10188, BGB-21447, Ociperlimab (BGB-A1217), Surzebiclimab (BGB-A425), BGB-15025, BGB-26808, Lifirafenib (BGB-283), BGB-3245, BGB-30813, and BGB-43395; antibodies, including Zanidatamab, BGB-A445, and BGB-A3055, as well as BGB-16673, a BTK-targeted CDAC, and BGB-24714, a SMAC mimetic. It has collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., Nanjing Leads Biolabs, Inc., EUSA Pharma, Assembly Biosciences, Inc., Bio-Thera Solutions, Ltd., and Nanjing Leads Biolabs Co., Ltd. The company was incorporated in 2010 and is based in Grand Cayman, the Cayman Islands.

Catalent stock logo

Catalent NYSE:CTLT

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules. The Pharma and Consumer Health segment offers formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations; and oral, nasal, inhaled, and topical dose forms. This segment also provides clinical supply services through manufacturing, packaging, storage, distribution, and inventory management for small-molecule drugs, protein-based biologics, and cell and gene therapies in clinical trials; and pre-clinical screening, formulation, analytical development, and current good manufacturing practices manufacturing at clinical and commercial scale for softgel capsule, Zydis fast-dissolve tablets, oral solid-dose formats, dry powder inhalers, and nasal delivery devices. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply solutions; fill and finish operations for injectable products; and integrated development and product supply chain solutions. It serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was founded in 1933 and is headquartered in Somerset, New Jersey.

Elanco Animal Health stock logo

Elanco Animal Health NYSE:ELAN

$14.90 -0.14 (-0.96%)
Closing price 07/11/2025 03:58 PM Eastern
Extended Trading
$14.90 +0.01 (+0.06%)
As of 07/11/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Mylan stock logo

Mylan NASDAQ:MYL

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS. The company also provides prescription products, such as EpiPen Auto-Injector; Perforomist Inhalation Solution; Dymista; Creon; and Influvac, as well as YUPELRI, an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary diseases. In addition, it markets OTC products, including Cold-EEZE, MidNite, Vivarin, Brufen, CB12, and EndWarts. The company offers its products to therapeutic areas, such as cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women's health. Its customers include retail pharmacies, wholesalers and distributors, payers, and insurers and governments, as well as institutions, such as hospitals. Mylan N.V. has collaboration and license agreements with Pfizer Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; Fujifilm Kyowa Kirin Biologics Co. Ltd; and Revance Therapeutics, Inc. The company was founded in 1961 and is based in Hatfield, the United Kingdom.

Sarepta Therapeutics stock logo

Sarepta Therapeutics NASDAQ:SRPT

$18.17 -0.90 (-4.72%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$18.16 -0.01 (-0.08%)
As of 07/11/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.